T1	Person 0 3	Age
T2	Value 4 14	≥ 18 years
R1	Has_value Arg1:T1 Arg2:T2	
T3	Person 16 19	Age
T4	Value 20 30	≥ 12 years
R2	Has_value Arg1:T3 Arg2:T4	
T5	Condition 49 62	bone sarcomas
A1	Optional T5
R3	AND Arg1:T5 Arg2:T3	
*	OR T1 T5
T6	Procedure 66 80	Histologically
T7	Value 81 90	confirmed
R4	Has_value Arg1:T6 Arg2:T7	
T8	Condition 158 169;178 185	soft-tissue sarcoma
T9	Qualifier 147 157	high grade
T10	Qualifier 136 146	metastatic
T11	Temporal 118 127	recurrent
T12	Qualifier 104 116	unresectable
*	OR T9 T10 T11 T12
T13	Condition 173 185	bone sarcoma
T14	Scope 158 185	soft-tissue or bone sarcoma
*	OR T8 T13
T15	Scope 104 157	unresectable, recurrent, and/or metastatic high grade
R5	Has_scope Arg1:T14 Arg2:T15	
T16	Condition 220 240	soft tissue sarcomas
T17	Condition 242 256	leiomyosarcoma
T18	Condition 298 309	liposarcoma
T19	Qualifier 258 279	poorly differentiated
T20	Qualifier 280 297	de-differentiated
*	OR T20 T19
T21	Scope 258 297	poorly differentiated/de-differentiated
R6	Has_scope Arg1:T18 Arg2:T21	
T22	Condition 351 358	sarcoma
T23	Qualifier 334 350	undifferentiated
T24	Qualifier 322 333	pleomorphic
T25	Qualifier 311 321	high grade
T26	Condition 359 362	MFH
T27	Condition 367 383	synovial sarcoma
*	OR T26 T22
T28	Scope 351 383	sarcoma/MFH and synovial sarcoma
T29	Scope 311 350	high grade pleomorphic undifferentiated
R7	Has_scope Arg1:T28 Arg2:T29	
T30	Condition 390 403	bone sarcomas
T31	Condition 405 418	Ewing sarcoma
T32	Condition 420 432	osteosarcoma
T33	Condition 438 452	chondrosarcoma
T34	Qualifier 454 471	de-differentiated
T35	Qualifier 475 486	mesenchymal
*	OR T35 T34
T36	Scope 454 486	de-differentiated or mesenchymal
R8	Has_scope Arg1:T33 Arg2:T36	
T37	Scope 404 488	(Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal])
*	OR T31 T32 T33
R9	Subsumes Arg1:T30 Arg2:T37	
T38	Scope 242 383	leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH and synovial sarcoma
R10	Subsumes Arg1:T16 Arg2:T38	
*	OR T16 T30
T39	Grammar_Error 386 389	and
T40	Scope 220 488	soft tissue sarcomas (leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH and synovial sarcoma), and bone sarcomas (Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal])
R11	Subsumes Arg1:T14 Arg2:T40	
R12	AND Arg1:T14 Arg2:T6	
T41	Measurement 491 514	ECOG Performance Status
T42	Value 518 524	0 or 1
R13	Has_value Arg1:T41 Arg2:T42	
T43	Condition 548 566	measurable disease
T44	Procedure 570 572;577 582	CT scans
T45	Procedure 573 582	MRI scans
*	OR T44 T45
T46	Scope 570 582	CT/MRI scans
R14	AND Arg1:T46 Arg2:T43	
T47	Procedure 618 625	imaging
T48	Temporal 609 617	Baseline
R15	Has_temporal Arg1:T47 Arg2:T48	
T49	Temporal 644 668	within 30 days of dosing
T50	Reference_point 662 668	dosing
R16	Has_index Arg1:T49 Arg2:T50	
R17	Has_temporal Arg1:T47 Arg2:T49	
T51	Non-query-able 671 811	At least one site of accessible disease for pre- and post-treatment core biopsies for at least 20 patients per arm on the expansion cohorts.
T52	Multiplier 840 843	1-3
T53	Temporal 844 849	prior
T54	Procedure 850 868	systemic therapies
T55	Qualifier 876 894	metastatic setting
R18	Has_qualifier Arg1:T54 Arg2:T55	
R19	Has_temporal Arg1:T54 Arg2:T53	
R20	Has_multiplier Arg1:T54 Arg2:T52	
T56	Condition 897 920	Adequate organ function
T57	Temporal 921 945	within 14 days of dosing
T58	Reference_point 939 945	dosing
R21	Has_index Arg1:T57 Arg2:T58	
R22	Has_temporal Arg1:T56 Arg2:T57	
T59	Non-query-able 947 1027	Must be willing to provide and have available archival tissue for PD-L1 testing.
T60	Post-eligibility 1029 1065	Written, voluntary informed consent.
T61	Non-query-able 1029 1065	Written, voluntary informed consent.
T62	Person 1083 1088	women
T63	Person 1075 1078	men
*	OR T62 T63
T64	Condition 1092 1114	childbearing potential
T65	Procedure 1156 1169	birth control
T66	Temporal 1170 1199	from providing signed consent
T67	Reference_point 1175 1199	providing signed consent
R23	Has_index Arg1:T66 Arg2:T67	
T68	Temporal 1204 1253	for 120 days after last study drug administration
T69	Reference_point 1223 1253	last study drug administration
R24	Has_index Arg1:T68 Arg2:T69	
R25	Has_temporal Arg1:T65 Arg2:T66	
R26	Has_temporal Arg1:T65 Arg2:T68	
T70	Scope 1075 1114	men and women of childbearing potential
A2	Optional T70
R27	AND Arg1:T70 Arg2:T65	
T71	Non-query-able 1067 1254	Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 120 days after last study drug administration.
T72	Non-query-able 1255 1377	Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause.
T73	Person 1255 1260	Women
T74	Condition 1264 1286	childbearing potential
T75	Condition 1295 1309	pre-menopausal
T76	Person 1310 1315	women
T77	Person 1320 1325	women
T78	Temporal 1326 1376	within the first 2 years of the onset of menopause
T79	Reference_point 1354 1376	the onset of menopause
R28	Has_index Arg1:T78 Arg2:T79	
T80	Condition 1387 1409	childbearing potential
T81	Person 1378 1383	Women
T82	Measurement 1431 1445	pregnancy test
T83	Value 1422 1430	negative
R29	Has_value Arg1:T82 Arg2:T83	
T84	Temporal 1446 1471	≤ 72 hours prior to Day 1
T85	Reference_point 1466 1471	Day 1
R30	Has_index Arg1:T84 Arg2:T85	
R31	Has_temporal Arg1:T82 Arg2:T84	
T86	Scope 1378 1409	Women of childbearing potential
A3	Optional T86
R32	AND Arg1:T86 Arg2:T82	
T87	Procedure 1504 1517	birth control
T88	Condition 1527 1545	surgically sterile
T89	Device 1547 1561	barrier device
T90	Device 1563 1569	condom
T91	Device 1571 1580	diaphragm
T92	Scope 1563 1580	condom, diaphragm
*	OR T91 T90
R33	Has_scope Arg1:T89 Arg2:T92	
T93	Device 1583 1601	contraceptive coil
T94	Device 1603 1628	intrauterine device (IUD)
T95	Procedure 1634 1644	abstinence
*	OR T88 T89 T93 T94 T95
T96	Grammar_Error 1630 1633	and
T97	Scope 1527 1644	surgically sterile, barrier device (condom, diaphragm), contraceptive coil, intrauterine device (IUD), and abstinence
R34	Subsumes Arg1:T87 Arg2:T97	
T98	Observation 1647 1662	Life expectancy
T99	Value 1666 1675	>12 weeks
R35	Has_value Arg1:T98 Arg2:T99	
T100	Condition 1692 1722	central nervous system disease
T101	Procedure 1779 1791	radiotherapy
T102	Procedure 1795 1802	surgery
T103	Condition 1815 1837	CNS metastatic disease
R36	AND Arg1:T102 Arg2:T103	
R37	AND Arg1:T101 Arg2:T103	
*	OR T101 T102
T104	Condition 1866 1886	clinical progression
T105	Negation 1846 1853	without
R38	Has_negation Arg1:T104 Arg2:T105	
T106	Temporal 1887 1926	for at least 4 weeks prior to screening
T107	Reference_point 1917 1926	screening
R39	Has_index Arg1:T106 Arg2:T107	
R40	Has_temporal Arg1:T104 Arg2:T106	
T108	Condition 1965 1981	brain metastases
T109	Qualifier 1955 1964	enlarging
T110	Qualifier 1948 1951	new
*	OR T109 T110
T111	Scope 1948 1964	new or enlarging
R41	Has_scope Arg1:T108 Arg2:T111	
T112	Negation 1933 1935	no
R42	Has_negation Arg1:T108 Arg2:T112	
T113	Drug 1995 2003	steroids
T114	Negation 1991 1994	off
R43	Has_negation Arg1:T113 Arg2:T114	
T115	Temporal 2004 2058	for at least 7 days before first dose of pembrolizumab
T116	Reference_point 2031 2058	first dose of pembrolizumab
T117	Drug 2045 2058	pembrolizumab
R44	AND Arg1:T116 Arg2:T117	
R45	Has_index Arg1:T115 Arg2:T116	
R46	Has_temporal Arg1:T113 Arg2:T115	
A4	Optional T100
T118	Scope 1779 2058	radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening, have no evidence of new or enlarging brain metastases, and are off steroids for at least 7 days before first dose of pembrolizumab
R47	Has_scope Arg1:T100 Arg2:T118	
